Advertisement
Advertisement

FBRX

FBRX logo

Forte Biosciences, Inc. Common Stock

29.22
USD
Sponsored
0.00
0.00%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

29.24

+0.02
+0.07%

FBRX Earnings Reports

Positive Surprise Ratio

FBRX beat 18 of 28 last estimates.

64%

Next Report

Date of Next Report
Mar 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.23
Implied change from Q3 25 (Revenue/ EPS)
--
/
+24.24%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-49.80%

Forte Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, FBRX reported earnings of -0.99 USD per share (EPS) for Q3 25, beating the estimate of -1.08 USD, resulting in a 9.07% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -1.23 USD, with revenue projected to reach -- USD, implying an increase of 24.24% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Forte Biosciences, Inc. Common Stock reported EPS of -$0.99, beating estimates by 9.07%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.73%, changed from $13.84 before the earnings release to $14.08 the day after.
The next earning report is scheduled for Mar 26, 2026.
Based on 7 analysts, Forte Biosciences, Inc. Common Stock is expected to report EPS of -$1.23 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement